about
NK Cell Inflammation in the Clinical Outcome of Colorectal CarcinomaMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsA cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods.Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceMinimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisA Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia.CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damageDeregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?Treatment of Low-Blast Count AML using Hypomethylating Agents.Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis.Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes.Clinical significance of CD38 expression in chronic lymphocytic leukemia.Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian RegRituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.
P50
Q26991949-E295C0D8-0952-47BC-867A-690F2F6CF565Q28073464-35BA8757-E300-44F2-8A11-B9739B19A00CQ30251621-20534CD4-652C-4830-8565-75BC4128AADFQ30810795-E29A2322-6E82-4EA8-907D-DD7472042D76Q33358780-148B2B54-16FF-46BF-863B-C42B20A86761Q33378392-F6B552A2-7F40-46DA-94DD-8A985F192220Q33410699-31D07DF5-3DED-4EDE-A434-FAFC7AF65B93Q33489476-D1E66C2A-E672-4E67-B7CD-959D5B962AC7Q33607015-1BB8144E-9323-4136-B6BE-83E25AC39C9DQ33815986-9B3C23DD-2A67-4F55-B6A1-BB862BB58696Q33877952-6F37870C-97BB-4357-ACA1-07254D590D50Q35104356-942CE003-A768-4FBD-8939-F67419A897C3Q35717883-A8157332-657D-4D6C-B21D-81E1588FDBD2Q36420752-B1152D6D-DD19-4DED-A70E-1B416914D0C6Q36739038-AD8D8F9A-AFF6-4ECF-B5C7-E5AEB2A95CE2Q37160624-1B2434D1-B231-4761-8B0C-6F08CFB11860Q38161965-A94952C4-AB00-4696-8ACF-563A4969A89FQ38269513-EF70078B-BC3C-403F-BE1E-1FF5D2F98EC1Q38368123-E99A67F2-EFF7-4C6F-8583-A6A2B0DE699EQ38851329-B5CD53F6-77B3-4066-8380-CC209C1B3BC5Q39032841-09D74C14-657D-42CB-8750-DB7E309AD1D4Q39429687-C681D6BD-DB02-454B-9C86-F53F9EF36D0CQ40366836-DBECB5AE-F588-4ACA-B7A3-6873D3975725Q40788034-E3FFB2B2-8F1C-4482-A970-75B19C4C6944Q40793299-0F6874F0-E394-44D5-BDFA-E2A5CD29FE75Q40896172-D87CAABC-138B-49B4-88BA-99912AD91E17Q40983463-59168948-F2C3-4618-932A-79E8BD77FE64Q41237697-504460D3-C4AE-4F13-B06D-DA8632A5BB3BQ42063125-6EB335AD-22B0-492D-9153-6E1EA1DF1FA1Q42166373-AE7D1905-1657-4644-A809-341EA0457CB9Q43408296-D3EFC55F-57D9-4D9F-B114-06B6579B20C3Q43584950-07E82650-1916-4B79-933E-C43F33C1CE2EQ43673854-4EE5CECF-9877-44E1-A769-1FCD277BCE0BQ43775864-E324553F-FEBA-4F7F-86EB-5358CB0540A0Q43984339-89938AF9-1912-4745-9520-0AA7DD767661Q44023853-F81B1F56-D667-42F4-9C8A-540C549C30ECQ44409582-A29ACBFB-96A8-4ECB-9806-56BF06A7AC39Q44630730-51A25493-284F-46A7-AF13-5B7718E09334Q45191343-771E4BBD-BEFF-4036-96CB-A8C8904406F3Q45385619-951B5C95-4F74-42B5-8BE6-A71779EE372C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Buccisano
@ast
Francesco Buccisano
@en
Francesco Buccisano
@es
Francesco Buccisano
@sl
type
label
Francesco Buccisano
@ast
Francesco Buccisano
@en
Francesco Buccisano
@es
Francesco Buccisano
@sl
prefLabel
Francesco Buccisano
@ast
Francesco Buccisano
@en
Francesco Buccisano
@es
Francesco Buccisano
@sl
P106
P1153
6701374425
P21
P31
P496
0000-0003-4320-9253